Punjab, April 27 -- Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia.HOUSTON, April 27, 2026 /PRNewswire/ - Cellenkos(R), Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia. Aplastic anemia, a rare and life-threatening blood disorder, continues to present a significant challenge for thousands of patients who fall outside the reach of current standard treatments. Aplastic Anemia develops because of an autoimmu...